
Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of sarcoma that occur spontaneously or in association with neurofibromatosis type 1 (NF-1). This study aimed to clinically differentiate these types of MPNSTs.The study reviewed 95 patients diagnosed with and treated for MPNST at Yonsei University Health System, Seoul, Korea over a 27-year period. The clinical characteristics, prognostic factors, and treatment outcomes of sporadic MPNST (sMPNST) and NF-1 associated MPNST (NF-MPNST) cases were compared.Patients with NF-MPNST had a significantly lower median age (32 years vs. 45 years for sMPNST, p=0.012), significantly larger median tumor size (8.2 cm vs. 5.0 cm for sMPNST, p < 0.001), and significantly larger numbers of imaging studies and surgeries (p=0.004 and p < 0.001, respectively). The 10-year overall survival (OS) rate of the patients with MPNST was 52±6%. Among the patients with localized MPNST, patients with NF-MPNST had a significantly lower 10-year OS rate (45±11% vs. 60±8% for sMPNST, p=0.046). Univariate analysis revealed the resection margin, pathology grade, and metastasis to be significant factors affecting the OS (p=0.001, p=0.020, and p < 0.001, respectively). Multivariate analysis of the patients with localized MPNST identified R2 resection and G1 as significant prognostic factors for OS.NF-MPNST has different clinical features from sMPNST and requires more careful management. Further study will be needed to develop specific management plans for NF-MPNST.
Adult, Male, Neurofibromatosis 1, Neurofibromatoses, Adolescent, Biopsy, 610, Practice Patterns, Young Adult, Neurofibromatosis 1/mortality*, Peripheral Nervous System Neoplasms, Risk Factors, Neoplasms, Peripheral Nervous System, 80 and over, Humans, Neoplasm Metastasis, Practice Patterns, Physicians', Child, Peripheral Nervous System Neoplasms/therapy*, Combined Modality Therapy/adverse effects, Neurofibromatosis 1/diagnosis, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Physicians', Disease Management, Sarcoma, 600, Middle Aged, Survival Analysis, Combined Modality Therapy, Tumor Burden, Treatment Outcome, Combined Modality Therapy/methods, Neurofibromatosis 1/therapy*, Peripheral Nervous System Neoplasms/diagnosis, Original Article, Female, Neoplasms/mortality*, Neoplasm Grading, Neurilemmoma
Adult, Male, Neurofibromatosis 1, Neurofibromatoses, Adolescent, Biopsy, 610, Practice Patterns, Young Adult, Neurofibromatosis 1/mortality*, Peripheral Nervous System Neoplasms, Risk Factors, Neoplasms, Peripheral Nervous System, 80 and over, Humans, Neoplasm Metastasis, Practice Patterns, Physicians', Child, Peripheral Nervous System Neoplasms/therapy*, Combined Modality Therapy/adverse effects, Neurofibromatosis 1/diagnosis, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Physicians', Disease Management, Sarcoma, 600, Middle Aged, Survival Analysis, Combined Modality Therapy, Tumor Burden, Treatment Outcome, Combined Modality Therapy/methods, Neurofibromatosis 1/therapy*, Peripheral Nervous System Neoplasms/diagnosis, Original Article, Female, Neoplasms/mortality*, Neoplasm Grading, Neurilemmoma
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 40 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
